Table 1. Patient Characteristics.
| Factors | Total |
|---|---|
| Total | 35 |
| Year of DLI | |
| 2004-2006 | 19 |
| 2007-2009 | 16 |
| Age at transplant | |
| Median (range), IQR | 51 (1-66), (44-58) |
| DLI dose | |
| 1 × 108 CD 3+/kg | 15 |
| 0.5 × 108 CD 3+/kg | 20 |
| Gender | |
| Male | 18 |
| Female | 17 |
| Donor type | |
| Sibling | 30 |
| URD | 5 |
| Disease | |
| AML | 15 (43%) |
| MDS/MPD | 7 (20%) |
| NHL/Hodgkins | 5 (14%) |
| CLL | 3 (8.5%) |
| Multiple myeloma | 2 (5.5%) |
| ALL, prolymphocytic leukemia | 3 (9%) |
| JMML | |
| Disease status at | |
| CR* | 3 (8.5%) |
| Marrow only | 22 (63%) |
| EM disease | 7 (20%) |
| EM + marrow | 3 (8.5%) |
| Months from HCT to relapse (range) | 7 (2.7-105) |
| Follow-up among survivors | |
| Median (range) in years | 2.3 (0.3-6.2) |
NHL indicates non-Hodgkin lymphoma; CLL, chronic lymphocytic leukemia; ALL, acute lymphocytic leukemia; JMML, juvenile myelomonocytic leukemia; URD, unrelated donor; IQR, interquartile range; EM, extramedullary.
*
All 3 patients who entered the trial in CR were AML patients who received reinduction chemotherapy before enrollment on this trial.